Skip to main content

Table 6 The frequency of adverse events mild to moderate grades from day 1 to day 7 (related or not) after treatment initiation

From: Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial

 

AS-SMP

3 days (A)

(N = 476)

AS-SMP

24 hours (B)

(N = 458)

AL

3 days (C)

(N = 450)

P-value

Vomiting – n (%)

22 (4.6)

32 (7.0)

10 (2.2)

0.003

Nausea-n (%)

15 (3.2)

19 (4.2)

14 (3.1)

0.6

Headache – n (%)

5 (1.1)

10 (2.2)

7 (1.6)

0.4

Weakness – n (%)

11 (2.3)

5 (1.1)

2 (0.4)

0.04

Anorexia – n (%)

16 (3.4)

11 (2.4)

17 (3.8)

0.5

Dizziness – n (%)

13 (2.7)

14 (3.1)

10 (2.2)

0.7

Diarrhea – n (%)

3 (0.6)

15 (3.3)

6 (1.3)

0.006

Rash – n (%)

3 (0.6)

5 (1.1)

1 (0.2)

0.3

Abdominal pain – n (%)

21 (4.4)

21 (4.6)

17 (3.8)

0.8

Others* – n (%)

15 (3.2)

10 (2.2)

12 (2.7)

0.7

Total – n (%)

124 (26.1)

142 (31.0)

96 (21.3)

0.004

  1. Data are no. (%) of participants with the sign or symptom from day 1 to day 7 after treatment
  2. * Others are: infections (skin, respiratory, intestinal...) pains...